Back to Search
Start Over
POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting.
- Source :
-
Value in Health . 2022 Supplement, Vol. 25 Issue 1, pS23-S23. 1p. - Publication Year :
- 2022
- Subjects :
- *MIGRAINE
Subjects
Details
- Language :
- English
- ISSN :
- 10983015
- Volume :
- 25
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Value in Health
- Publication Type :
- Academic Journal
- Accession number :
- 154761426
- Full Text :
- https://doi.org/10.1016/j.jval.2021.11.101